人恶性胶质瘤细胞裸鼠脑原位移植瘤FPR表达与VEGF关系  

Relationship between expression of formylpeptide receptor in the orthotopic transplantation tumors of malignant human glioblastoma cell line U87

作　　者：刘宏[1] 卞修武[1] 赵雯[1] 陈代伦[1] 陈剑鸿[1] 冯玉慧[1] 徐承平[1] 

机构地区：[1]第三军医大学西南医院病理研究所,重庆400038

出　　处：《临床与实验病理学杂志》2006年第5期600-603,共4页Chinese Journal of Clinical and Experimental Pathology

基　　金：国家自然科学基金资助(No30370552u)

摘　　要：目的观测甲酰肽受体(formylpeptide receptor,FPR)在人恶性胶质瘤细胞系U87细胞裸鼠脑原位移植瘤组织中的表达,以及与血管内皮生长因子(VEGF)的关系,探讨FPR在恶性胶质瘤血管生成过程中的作用。方法培养U87细胞,以立体定向注射技术制作U87裸鼠脑原位移植瘤模型;采用间接免疫荧光染色在激光共聚焦显微镜下分别观测FPR在U87细胞和移植瘤组织的表达;免疫组化方法检测VEGF在U87细胞裸鼠脑移植瘤上的表达。结果培养的U87细胞及其原位移植瘤组织均可见FPR表达,定位于瘤细胞胞膜,VEGF阳性着色主要位于胞质,两者阳性表达程度呈正相关性。结论人恶性胶质瘤细胞系U87细胞裸鼠脑原位移植瘤组织存在FPR表达,与VEGF的产生密切相关,在胶质瘤血管生成过程中可能起重要作用。Purpose To observe the relationship between the expression of formylpeptide receptor （FPR） and production of vascular endothelial growth factor （VEGF） in human glioma ceil line U87 orthotopic transplantation tumors in the brains of nude mice, and to explore the potential roles of FPR during the angiogenesis of malignant glioma. Methods An orthotopic implantation of U87 cells with stereotactic technique in nude mouse brain was used. By indirect immunofluorescence staining combined with confocal laser scanning microscopy, the expression and localization of FPR in U87 cells and its orthotopic transplantation tumor tissues were detected. Results FPR was expressed in U87 cells and its orthotopic transplantation tumor tissues. FPR was n,ainly located at plasma membranes whereas VEGF was mainly found in the cytoplasm of neoplastic cells. In addition, the expression levels of FPR and VEGF were positively correlated in the tumor cells. Conclusions The human glioblastoma cell line, U87 and its orthotopic transplantation tumor have the formylpeptide receptor （FPR） , whose expression and activation are closely correlated with production of VEGF. Thus it might be of much importance in progression and neoangiogenesis of malignant gliomas.

关 键 词：脑肿瘤 胶质瘤 甲酰化肽受体 血管内皮生长因子 血管生成 

分 类 号：R739.41[医药卫生—肿瘤] R392.114[医药卫生—临床医学]